CDER's Generational Shift: Many New Reviewers With Little Experience
This article was originally published in RPM Report
Executive Summary
While the center for drugs has enjoyed an influx of new reviewers in the last few years, the hiring frenzy has resulted in a significant shift in CDER's makeup: 38% of reviewers in the Office of New Drugs have less than two years of on-the-job experience. Office of New Drugs director John Jenkins discusses the challenges with training the new recruits, and how industry should adapt
You may also be interested in...
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities, with Director Janet Woodcock scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities. Janet Woodcock is left scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.
Show Me The Money: Salaries, Red Tape Challenge FDA Recruiting
FDA’s drug center continues to operate with a staffing shortage at a time of tremendous pressure to implement new authorities. Janet Woodcock is left scrambling to find senior managers to lead top initiatives. Direct hiring authority has helped but doesn’t fully address FDA’s recruiting challenges: too much red tape and too little money.